Resmetirom proves positive for NASH with liver fibrosis

Katrina Ray

DOI: https://doi.org/10.1038/s41575-024-00909-0

2024-02-16

Nature Reviews Gastroenterology & Hepatology

Abstract:Positive phase III results have been reported for resmetirom (a thyroid hormone receptor β-selective agonist) for the treatment of nonalcoholic steatohepatitis (NASH; also known as metabolic dysfunction-associated steatohepatitis (MASH)) with liver fibrosis. In a phase III, randomized controlled trial, 966 patients with biopsy-confirmed NASH and liver fibrosis (stage F1B, F2 or F3) were randomly assigned to receive a once-daily dose of 80 mg resmetirom, 100 mg resmetirom or placebo for 52 weeks. Resolution of NASH with no worsening of fibrosis was achieved in 25.9% of the 80 mg group and 29.9% of the 100 mg group, compared with 9.7% in the placebo group ( P < 0.001 for both comparisons). Improvement in fibrosis by at least one stage with no worsening of disease activity scores occurred in 24.2% of the 80 mg group and 25.9% of patients in the 100 mg group, versus 14.2% in the placebo group ( P < 0.001 for both comparisons). Moreover, LDL cholesterol levels were also reduced by resmetirom (from baseline to week 24, –13.6% in the 80 mg group, –16.3% in the 100 mg group, 0.1% in the placebo group; P < 0.001).

gastroenterology & hepatology